Since Liu et al. first directly investigated the diagnostic and prognostic potentials of preoperative testing of thyroid fine-needle aspiration biopsy (FNAB) specimens for the TERT promoter mutations in thyroid cancer [12], a significant interest in TERT promoter mutations (mainly C228T and C250T) focused on the frequency of these mutations in different subtypes of thyroid cancer and their association with clinicopathological features and outcomes of thyroid cancer has accumulated. The gene discussed is TERT; the disease is thyroid cancer.